{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:57:22Z","timestamp":1766401042132,"version":"3.40.5"},"reference-count":117,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Having in mind that diabetes mellitus (DM) and obesity are some of the\ngreatest health challenges of the modern era, diabetic cardiomyopathy (DCM) is becoming more\nand more recognized in clinical practice.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Main Text:<\/jats:title>\n<jats:p> Initially, DM is asymptomatic, but it may progress to diastolic and then systolic left\nventricular dysfunction, which results in congestive heart failure. A basic feature of this DM complication\nis the absence of hemodynamically significant stenosis of the coronary blood vessels.\nClinical manifestations are the result of several metabolic disorders that are present during DM progression.\nThe complexity of metabolic processes, along with numerous regulatory mechanisms, has\nbeen the subject of research that aims at discovering new diagnostic (e.g. myocardial strain with\nechocardiography and cardiac magnetic resonance) and treatment options. Adequate glycaemic control\nis not sufficient to prevent or reduce the progression of DCM. Contemporary hypoglycemic\nmedications, such as sodium-glucose transport protein 2 inhibitors, significantly reduce the frequency\nof cardiovascular complications in patients with DM. Several studies have shown that, unlike\nthe above-stated medications, thiazolidinediones and dipeptidyl peptidase-4 inhibitors are associated\nwith deterioration of heart failure.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> Imaging procedures, especially myocardial strain with echocardiography and cardiac\nmagnetic resonance, are useful to identify the early signs of DCM. Research and studies regarding\nnew treatment options are still \u201cin progress\u201d.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570161119999201102213214","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T07:54:51Z","timestamp":1604476491000},"page":"487-498","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Diabetic Cardiomyopathy: Clinical and Metabolic Approach"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4966-0168","authenticated-orcid":true,"given":"Dragan B.","family":"Djordjevic","sequence":"first","affiliation":[{"name":"Medical Faculty, University of Nis, Bulevar Dr. Zoran Djindjic 8, 18000 Nis,Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9861-8447","authenticated-orcid":true,"given":"Goran","family":"Koracevic","sequence":"additional","affiliation":[{"name":"Clinical Center Nis, Bulevar Dr. Zoran Djindjic 48, 18000 Nis,Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8479-7226","authenticated-orcid":true,"given":"Aleksandar D.","family":"Djordjevic","sequence":"additional","affiliation":[{"name":"Uniklinik Rostock, Kardiologie, Schillngallee 35, 18057 Rostock,Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0685-2605","authenticated-orcid":true,"given":"Dragan B.","family":"Lovic","sequence":"additional","affiliation":[{"name":"Clinic for Internal Diseases Intermedica, Singidunum University Nis, Jovana Ristica 20\/III-2, 1800 Nis,United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12933-017-0506-x","volume":"16","author":"Lorenzo-Almor\u00f3s A.","year":"2017","unstructured":"Lorenzo-Almor\u00f3s A.; Tu\u00f1\u00f3n J.; Orejas M.; Cort\u00e9s M.; Egido J.; Lorenzo \u00d3.; Diagnostic approaches for diabetic cardiomyopathy. Cardiovasc Diabetol 2017,16(1),28","journal-title":"Cardiovasc Diabetol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3803\/EnM.2017.32.2.171","volume":"32","author":"Williams L.J.","year":"2017","unstructured":"Williams L.J.; Nye B.G.; Wende A.R.; Diabetes-related cardiac dysfunction. Endocrinol Metab (Seoul) 2017,32(2),171-179","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","volume":"30","author":"Rubler S.","year":"1972","unstructured":"Rubler S.; Dlugash J.; Yuceoglu Y.Z.; Kumral T.; Branwood A.W.; Grishman A.; New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972,30(6),595-602","journal-title":"Am J Cardiol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00125-017-4390-4","volume":"61","author":"Jia G.","year":"2018","unstructured":"Jia G.; Whaley-Connell A.; Sowers J.R.; Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia 2018,61(1),21-28","journal-title":"Diabetologia"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"Stratton I.M.","year":"2000","unstructured":"Stratton I.M.; Adler A.I.; Neil H.A.; Matthews D.R.; Manley S.E.; Cull C.A.; Hadden D.; Turner R.C.; Holman R.R.; Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000,321(7258),405-412","journal-title":"BMJ"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00125-019-4958-2","volume":"62","author":"Bowes D.C.","year":"2019","unstructured":"Bowes D.C.; Lillian F.; Lien F.L.; Butler J.; Clinical aspects of heart failure in individuals with diabetes. Diabetologia 2019,62,1529-38","journal-title":"Diabetologia"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.2337\/db13-0683","volume":"62","year":"2013","unstructured":"Litwin SE. Diabetes and the heart: is there objective evidence of a human diabetic cardiomyopathy? Diabetes 2013,62,3329-3330","journal-title":"Diabetes"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2174\/1570161117666190405165911","volume":"18","author":"Lovic D.","year":"2020","unstructured":"Lovic D.; Piperidou A.; Zografou I.; Grassos H.; Pittaras A.; Manolis A.; The growing epidemic of diabetes mellitus. Curr Vasc Pharmacol 2020,18(2),104-109","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","volume":"29","author":"MacDonald M.R.","year":"2008","unstructured":"MacDonald M.R.; Petrie M.C.; Varyani F.; Ostergren J.; Michelson E.L.; Young J.B.; Solomon S.D.; Granger C.B.; Swedberg K.; Yusuf S.; Pfeffer M.A.; McMurray J.J.; Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J CHARM Investigators2008,29(11),1377-1385","journal-title":"Eur Heart J"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ejhf.1170","volume":"20","author":"Seferovi\u0107 P.M.","year":"2018","unstructured":"Seferovi\u0107 P.M.; Petrie M.C.; Filippatos G.S.; Anker S.D.; Rosano G.; Bauersachs J.; Paulus W.J.; Komajda M.; Cosentino F.; de Boer R.A.; Farmakis D.; Doehner W.; Lambrinou E.; Lopatin Y.; Piepoli M.F.; Theodorakis M.J.; Wiggers H.; Lekakis J.; Mebazaa A.; Mamas M.A.; Tsch\u00f6pe C.; Hoes A.W.; Seferovi\u0107 J.P.; Logue J.; McDonagh T.; Riley J.P.; Milinkovi\u0107 I.; Polovina M.; van Veldhuisen D.J.; Lainscak M.; Maggioni A.P.; Ruschitzka F.; McMurray J.J.V.; Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018,20(5),853-872","journal-title":"Eur J Heart Fail"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","volume":"132","author":"Cavender M.A.","year":"2015","unstructured":"Cavender M.A.; Steg P.G.; Smith S.C.; Eagle K.; Ohman E.M.; Goto S.; Kuder J.; Im K.; Wilson P.W.; Bhatt D.L.; Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: Outcomes at 4 years from the reduction of atherothrombosis for continued health (REACH) registry. Circulation REACH Registry Investigators2015,132(10),923-931","journal-title":"Circulation"},{"key":"ref=12","first-page":"213","volume":"23","author":"Amato L.","year":"1997","unstructured":"Amato L.; Paolisso G.; Cacciatore F.; Ferrara N.; Ferrara P.; Canonico S.; Varricchio M.; Rengo F.; Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. Diabetes Metab The Osservatorio Geriatrico Regione Campania Group1997,23(3),213-218","journal-title":"Diabetes Metab"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jacc.2005.02.093","volume":"46","author":"Doehner W.","year":"2005","unstructured":"Doehner W.; Rauchhaus M.; Ponikowski P.; Godsland I.F.; von Haehling S.; Okonko D.O.; Leyva F.; Proudler A.J.; Coats A.J.; Anker S.D.; Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 2005,46(6),1019-1026","journal-title":"J Am Coll Cardiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1249\/MSS.0b013e318295cdbb","volume":"45","author":"Roberts C.K.","year":"2013","unstructured":"Roberts C.K.; Little J.P.; Thyfault J.P.; Modification of insulin sensitivity and glycemic control by activity and exercise. Med Sci Sports Exerc 2013,45(10),1868-1877","journal-title":"Med Sci Sports Exerc"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","volume":"369","author":"Elliott W.J.","year":"2007","unstructured":"Elliott W.J.; Meyer P.M.; Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007,369(9557),201-207","journal-title":"Lancet"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","volume":"34","author":"Kannel W.B.","year":"1974","unstructured":"Kannel W.B.; Hjortland M.; Castelli W.P.; Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974,34(1),29-34","journal-title":"Am J Cardiol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.cardfail.2018.10.015","volume":"25","author":"Khan H.","year":"2019","unstructured":"Khan H.; Anker S.D.; Januzzi J.L.; McGuire D.K.; Sattar N.; Woerle H.J.; Butler J.; Heart failure epidemiology in patients with diabetes mellitus without coronary heart disease. J Card Fail 2019,25(2),78-86","journal-title":"J Card Fail"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/CIRCIMAGING.109.911438","volume":"3","author":"Velagaleti R.S.","year":"2010","unstructured":"Velagaleti R.S.; Gona P.; Chuang M.L.; Salton C.J.; Fox C.S.; Blease S.J.; Yeon S.B.; Manning W.J.; O\u2019Donnell C.J.; Relations of insulin resistance and glycemic abnormalities to cardiovascular magnetic resonance measures of cardiac structure and function: the Framingham Heart Study. Circ Cardiovasc Imaging 2010,3(3),257-263","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"H787","DOI":"10.1152\/ajpheart.00974.2005","volume":"291","author":"Samuelsson A-M.","year":"2006","unstructured":"Samuelsson A-M.; Bollano E.; Mobini R.; Larsson B.M.; Omerovic E.; Fu M.; Waagstein F.; Holm\u00e4ng A.; Hyperinsulinemia: effect on cardiac mass\/function, angiotensin II receptor expression, and insulin signaling pathways. Am J Physiol Heart Circ Physiol 2006,291(2),H787-H796","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","volume":"36","author":"Seferovi\u0107 P.M.","year":"2015","unstructured":"Seferovi\u0107 P.M.; Paulus W.J.; Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J 2015,36(27),1718-1727, 1727a-1727c","journal-title":"Eur Heart J"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00059-011-3429-4","volume":"36","author":"Maisch B.","year":"2011","unstructured":"Maisch B.; Alter P.; Pankuweit S.; Diabetic cardiomyopathy--fact or fiction? Herz 2011,36(2),102-115","journal-title":"Herz"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/1871530311313010006","volume":"13","author":"Dei Cas A.","year":"2013","unstructured":"Dei Cas A.; Spigoni V.; Ridolfi V.; Metra M.; Diabetes and chronic heart failure: from diabetic cardiomyopathy to therapeutic approach. Endocr Metab Immune Disord Drug Targets 2013,13(1),38-50","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.5152\/akd.2014.5115","volume":"14","author":"Lovic D.","year":"2014","unstructured":"Lovic D.; Erdine S.; Catako\u011flu A.B.; How to estimate left ventricular hypertrophy in hypertensive patients. Anadolu Kardiyol Derg 2014,14(4),389-395","journal-title":"Anadolu Kardiyol Derg"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.4070\/kcj.2015.45.4.266","volume":"45","author":"Yilmaz S.","year":"2015","unstructured":"Yilmaz S.; Canpolat U.; Aydogdu S.; Abboud H.E.; Diabetic cardiomyopathy; Summary of 41 years. Korean Circ J 2015,45(4),266-272","journal-title":"Korean Circ J"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","volume":"29","author":"Nagueh S.F.","year":"2016","unstructured":"Nagueh S.F.; Smiseth O.A.; Appleton C.P.; Byrd B.F.; Dokainish H.; Edvardsen T.; Flachskampf F.A.; Gillebert T.C.; Klein A.L.; Lancellotti P.; Marino P.; Oh J.K.; Popescu B.A.; Waggoner A.D.; Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016,29(4),277-314","journal-title":"J Am Soc Echocardiogr"},{"key":"ref=26","first-page":"411","volume":"55","author":"Trachanas K.","year":"2014","unstructured":"Trachanas K.; Sideris S.; Aggeli C.; Poulidakis E.; Gatzoulis K.; Tousoulis D.; Kallikazaros I.; Diabetic cardiomyopathy: from pathophysiology to treatment. Hellenic J Cardiol 2014,55(5),411-421","journal-title":"Hellenic J Cardiol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.amjcard.2010.10.024","volume":"107","author":"Jellis C.L.","year":"2011","unstructured":"Jellis C.L.; Stanton T.; Leano R.; Martin J.; Marwick T.H.; Usefulness of at rest and exercise hemodynamics to detect subclinical myocardial disease in type 2 diabetes mellitus. Am J Cardiol 2011,107(4),615-621","journal-title":"Am J Cardiol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.echo.2011.07.017","volume":"24","author":"Ernande L.","year":"2011","unstructured":"Ernande L.; Bergerot C.; Rietzschel E.R.; De Buyzere M.L.; Thibault H.; Pignonblanc P.G.; Croisille P.; Ovize M.; Groisne L.; Moulin P.; Gillebert T.C.; Derumeaux G.; Diastolic dysfunction in patients with type 2 diabetes mellitus: is it really the first marker of diabetic cardiomyopathy? J Am Soc Echocardiogr 2011,24(11),1268-1275.e1","journal-title":"J Am Soc Echocardiogr"},{"key":"ref=29","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1310265","volume":"2017","author":"Gilca G.E.","year":"2017","unstructured":"Gilca G.E.; Stefanescu G.; Badulescu O.; Tanase D.M.; Bararu I.; Ciocoiu M.; Diabetic cardiomyopathy: current approach and potential diagnostic and therapeutic targets. J Diabetes Res 2017,2017","journal-title":"J Diabetes Res"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1161\/01.CIR.0000072789.89096.10","volume":"107","author":"Scheuermann-Freestone M.","year":"2003","unstructured":"Scheuermann-Freestone M.; Madsen P.L.; Manners D.; Blamire A.M.; Buckingham R.E.; Styles P.; Radda G.K.; Neubauer S.; Clarke K.; Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 2003,107(24),3040-3046","journal-title":"Circulation"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jacc.2010.02.049","volume":"56","author":"Rijzewijk L.J.","year":"2010","unstructured":"Rijzewijk L.J.; Jonker J.T.; van der Meer R.W.; Lubberink M.; de Jong H.W.; Romijn J.A.; Bax J.J.; de Roos A.; Heine R.J.; Twisk J.W.; Windhorst A.D.; Lammertsma A.A.; Smit J.W.; Diamant M.; Lamb H.J.; Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J Am Coll Cardiol 2010,56(3),225-233","journal-title":"J Am Coll Cardiol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1161\/CIRCULATIONAHA.110.955542","volume":"122","author":"Ng A.C.T.","year":"2010","unstructured":"Ng A.C.T.; Delgado V.; Bertini M.; van der Meer R.W.; Rijzewijk L.J.; Hooi Ewe S.; Siebelink H.M.; Smit J.W.; Diamant M.; Romijn J.A.; de Roos A.; Leung D.Y.; Lamb H.J.; Bax J.J.; Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus. Circulation 2010,122(24),2538-2544","journal-title":"Circulation"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/cvr\/cvx018","volume":"113","author":"Chong C.R.","year":"2017","unstructured":"Chong C.R.; Clarke K.; Levelt E.; Metabolic remodelling in diabetic cardiomyopathy. Cardiovasc Res 2017,113(4),422-430","journal-title":"Cardiovasc Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1196\/annals.1341.019","volume":"1047","author":"Taegtmeyer H.","year":"2005","unstructured":"Taegtmeyer H.; Wilson C.R.; Razeghi P.; Sharma S.; Metabolic energetics and genetics in the heart. Ann N Y Acad Sci 2005,1047,208-218","journal-title":"Ann N Y Acad Sci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1161\/CIRCRESAHA.113.302095","volume":"113","author":"Kolwicz S.C.","year":"2013","unstructured":"Kolwicz S.C.; Purohit S.; Tian R.; Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ Res 2013,113(5),603-616","journal-title":"Circ Res"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nrendo.2015.216","volume":"12","author":"Jia G.","year":"2016","unstructured":"Jia G.; DeMarco V.G.; Sowers J.R.; Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol 2016,12(3),144-153","journal-title":"Nat Rev Endocrinol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/cvr\/cvp190","volume":"84","author":"Banerjee S.K.","year":"2009","unstructured":"Banerjee S.K.; McGaffin K.R.; Pastor-Soler N.M.; Ahmad F.; SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res 2009,84(1),111-118","journal-title":"Cardiovasc Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/j.bbadis.2017.10.035","volume":"1864","author":"Varma U.","year":"2018","unstructured":"Varma U.; Koutsifeli P.; Benson V.L.; Mellor K.M.; Delbridge L.M.D.; Delbridge D.M.L.; Molecular mechanisms of cardiac pathology in diabetes - Experimental insights. Biochim Biophys Acta Mol Basis Dis 2018,1864(5 Pt B),1949-1959","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"E578","DOI":"10.1152\/ajpendo.00093.2009","volume":"297","author":"Hue L.","year":"2009","unstructured":"Hue L.; Taegtmeyer H.; The Randle cycle revisited: a new head for an old hat. Am J Physiol Endocrinol Metab 2009,297(3),E578-E591","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1172\/JCI0214080","volume":"109","author":"Finck B.N.","year":"2002","unstructured":"Finck B.N.; Lehman J.J.; Leone T.C.; Welch M.J.; Bennett M.J.; Kovacs A.; Han X.; Gross R.W.; Kozak R.; Lopaschuk G.D.; Kelly D.P.; The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002,109(1),121-130","journal-title":"J Clin Invest"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"E923","DOI":"10.1152\/ajpendo.00360.2002","volume":"284","author":"Atkinson L.L.","year":"2003","unstructured":"Atkinson L.L.; Kozak R.; Kelly S.E.; Onay Besikci A.; Russell J.C.; Lopaschuk G.D.; Potential mechanisms and consequences of cardiac triacylglycerol accumulation in insulin-resistant rats. Am J Physiol Endocrinol Metab 2003,284(5),E923-E930","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/1440-1681.12370","volume":"42","author":"Chandramouli C.","year":"2015","unstructured":"Chandramouli C.; Varma U.; Stevens E.M.; Xiao R.P.; Stapleton D.I.; Mellor K.M.; Delbridge L.M.; Myocardial glycogen dynamics: new perspectives on disease mechanisms. Clin Exp Pharmacol Physiol 2015,42(4),415-425","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"H1194","DOI":"10.1152\/ajpheart.00002.2015","volume":"308","author":"Delbridge L.M.","year":"2015","unstructured":"Delbridge L.M.; Mellor K.M.; Taylor D.J.; Gottlieb R.A.; Myocardial autophagic energy stress responses--macroautophagy, mitophagy, and glycophagy. Am J Physiol Heart Circ Physiol 2015,308(10),H1194-H1204","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nrcardio.2017.35","volume":"14","author":"Delbridge L.M.D.","year":"2017","unstructured":"Delbridge L.M.D.; Mellor K.M.; Taylor D.J.; Gottlieb R.A.; Myocardial stress and autophagy: mechanisms and potential therapies. Nat Rev Cardiol 2017,14(7),412-425","journal-title":"Nat Rev Cardiol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pharmthera.2016.11.013","volume":"172","author":"Faria A.","year":"2017","unstructured":"Faria A.; Persaud S.J.; Cardiac oxidative stress in diabetes: Mechanisms and therapeutic potential. Pharmacol Ther 2017,172,50-62","journal-title":"Pharmacol Ther"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1039\/C5FO01341K","volume":"7","author":"Helou C.","year":"2016","unstructured":"Helou C.; Gadonna-Widehem P.; Robert N.; Branlard G.; Thebault J.; Librere S.; Jacquot S.; Mardon J.; Piquet-Pissaloux A.; Chapron S.; Chatillon A.; Niquet-L\u00e9ridon C.; Tessier F.J.; The impact of raw materials and baking conditions on Maillard reaction products, thiamine, folate, phytic acid and minerals in white bread. Food Funct 2016,7(6),2498-2507","journal-title":"Food Funct"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"5967","DOI":"10.1210\/en.2006-0728","volume":"147","author":"Aragno M.","year":"2006","unstructured":"Aragno M.; Mastrocola R.; Medana C.; Catalano M.G.; Vercellinatto I.; Danni O.; Boccuzzi G.; Oxidative stress-dependent impairment of cardiac-specific transcription factors in experimental diabetes. Endocrinology 2006,147(12),5967-5974","journal-title":"Endocrinology"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3389\/fendo.2017.00072","volume":"8","author":"Mishra P.K.","year":"2017","unstructured":"Mishra P.K.; Ying W.; Nandi S.S.; Bandyopadhyay G.K.; Patel K.K.; Mahata S.K.; Diabetic cardiomyopathy: An immunometabolic perspective. Front Endocrinol (Lausanne) 2017,8,72","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41419-017-0093-5","volume":"9","author":"Gu J.","year":"2018","unstructured":"Gu J.; Wang S.; Guo H.; Tan Y.; Liang Y.; Feng A.; Liu Q.; Damodaran C.; Zhang Z.; Keller B.B.; Zhang C.; Cai L.; Inhibition of p53 prevents diabetic cardiomyopathy by preventing early-stage apoptosis and cell senescence, reduced glycolysis, and impaired angiogenesis. Cell Death Dis 2018,9(2),82","journal-title":"Cell Death Dis"},{"key":"ref=50","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6143129","volume":"2016","author":"Le\u00f3n L.E.","year":"2016","unstructured":"Le\u00f3n L.E.; Rani S.; Fernandez M.; Larico M.; Calligaris S.D.; Subclinical detection of diabetic cardiomyopathy with microRNAs: challenges and perspectives. J Diabetes Res 2016,2016","journal-title":"J Diabetes Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nrg2290","volume":"9","author":"Filipowicz W.","year":"2008","unstructured":"Filipowicz W.; Bhattacharyya S.N.; Sonenberg N.; Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008,9(2),102-114","journal-title":"Nat Rev Genet"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/cvr\/cvw235","volume":"113","author":"Rawal S.","year":"2017","unstructured":"Rawal S.; Munasinghe P.E.; Shindikar A.; Paulin J.; Cameron V.; Manning P.; Williams M.J.; Jones G.T.; Bunton R.; Galvin I.; Katare R.; Down-regulation of proangiogenic microRNA-126 and microRNA-132 are early modulators of diabetic cardiac microangiopathy. Cardiovasc Res 2017,113(1),90-101","journal-title":"Cardiovasc Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fendo.2018.00002","volume":"9","author":"De Rosa S.","year":"2018","unstructured":"De Rosa S.; Arcidiacono B.; Chiefari E.; Brunetti A.; Indolfi C.; Foti D.P.; Type 2 diabetes mellitus and cardiovascular disease: genetic and epigenetic links. Front Endocrinol (Lausanne) 2018,9,2","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.2337\/db12-1648","volume":"62","author":"Paneni F.","year":"2013","unstructured":"Paneni F.; Volpe M.; L\u00fcscher T.F.; Cosentino F.; SIRT1, p66(Shc), and Set7\/9 in vascular hyperglycemic memory: bringing all the strands together. Diabetes 2013,62(6),1800-1807","journal-title":"Diabetes"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1093\/eurheartj\/ehv599","volume":"37","author":"Costantino S.","year":"2016","unstructured":"Costantino S.; Paneni F.; L\u00fcscher T.F.; Cosentino F.; MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart. Eur Heart J 2016,37(6),572-576","journal-title":"Eur Heart J"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1002\/jcp.27038","volume":"234","author":"Chengji W.","year":"2019","unstructured":"Chengji W.; Xianjin F.; Exercise protects against diabetic cardiomyopathy by the inhibition of the endoplasmic reticulum stress pathway in rats. J Cell Physiol 2019,234(2),1682-1688","journal-title":"J Cell Physiol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3390\/nu9050437","volume":"9","author":"Testa R.","year":"2017","unstructured":"Testa R.; Bonfigli A.R.; Prattichizzo F.; La Sala L.; De Nigris V.; Ceriello A.; The \u201cmetabolic memory\u201d theory and the early treatment of hyperglycemia in prevention of diabetic complication. Nutrients 2017,9(5),437","journal-title":"Nutrients"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(15)00044-3","volume":"3","author":"Udell J.A.","year":"2015","unstructured":"Udell J.A.; Cavender M.A.; Bhatt D.L.; Chatterjee S.; Farkouh M.E.; Scirica B.M.; Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2015,3(5),356-366","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","volume":"124","author":"Kenny H.C.","year":"2019","unstructured":"Kenny H.C.; Abel E.D.; Heart failure in type 2 diabetes mellitus impact of glucose-lowering agents, heart failure therapies, and novel therapeutic strategies. Circ Res 2019,124(1),121-141","journal-title":"Circ Res"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"9406","DOI":"10.1073\/pnas.0501744102","volume":"102","author":"Zhang H.","year":"2005","unstructured":"Zhang H.; Zhang A.; Kohan D.E.; Nelson R.D.; Gonzalez F.J.; Yang T.; Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 2005,102(26),9406-9411","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.amjmed.2004.10.010","volume":"117","author":"Shah M.","year":"2004","unstructured":"Shah M.; Kolandaivelu A.; Fearon W.F.; Pioglitazone-induced heart failure despite normal left ventricular function. Am J Med 2004,117(12),973-974","journal-title":"Am J Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2165\/00002018-200932030-00002","volume":"32","author":"Dormandy J.","year":"2009","unstructured":"Dormandy J.; Bhattacharya M.; van Troostenburg de Bruyn A.R.; Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from Proactive. Drug Saf Proactive investigators2009,32(3),187-202","journal-title":"Drug Saf"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","volume":"374","author":"Kernan W.N.","year":"2016","unstructured":"Kernan W.N.; Viscoli C.M.; Furie K.L.; Young L.H.; Inzucchi S.E.; Gorman M.; Guarino P.D.; Lovejoy A.M.; Peduzzi P.N.; Conwit R.; Brass L.M.; Schwartz G.G.; Adams H.P.; Berger L.; Carolei A.; Clark W.; Coull B.; Ford G.A.; Kleindorfer D.; O\u2019Leary J.R.; Parsons M.W.; Ringleb P.; Sen S.; Spence J.D.; Tanne D.; Wang D.; Winder T.R.; Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med IRIS Trial Investigators2016,374(14),1321-1331","journal-title":"N Engl J Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1161\/STROKEAHA.116.013977","volume":"48","author":"Lee M.","year":"2017","unstructured":"Lee M.; Saver J.L.; Liao H.W.; Lin C.H.; Ovbiagele B.; Pioglitazone for secondary stroke prevention: a systematic review and meta-analysis. Stroke 2017,48(2),388-393","journal-title":"Stroke"},{"key":"ref=65","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013927","volume":"7","author":"Liao H.W.","year":"2017","unstructured":"Liao H.W.; Saver J.L.; Wu Y.L.; Chen T.H.; Lee M.; Ovbiagele B.; Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open 2017,7(1)","journal-title":"BMJ Open"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.3390\/ijms19102869","volume":"19","author":"Dziubak A.","year":"2018","unstructured":"Dziubak A.; W\u00f3jcicka G.; Wojtak A.; Be\u0142towski J.; Metabolic effects of metformin in the failing heart. Int J Mol Sci 2018,19(10),2869","journal-title":"Int J Mol Sci"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"191","DOI":"10.7326\/M16-1901","volume":"166","author":"Crowley M.J.","year":"2017","unstructured":"Crowley M.J.; Diamantidis C.J.; McDuffie J.R.; Cameron C.B.; Stanifer J.W.; Mock C.K.; Wang X.; Tang S.; Nagi A.; Kosinski A.S.; Williams J.W.; Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med 2017,166(3),191-200","journal-title":"Ann Intern Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s11897-012-0102-z","volume":"9","author":"Horman S.","year":"2012","unstructured":"Horman S.; Beauloye C.; Vanoverschelde J.L.; Bertrand L.; AMP-activated protein kinase in the control of cardiac metabolism and remodeling. Curr Heart Fail Rep 2012,9(3),164-173","journal-title":"Curr Heart Fail Rep"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/cvr\/cvq066","volume":"87","author":"Xiao H.","year":"2010","unstructured":"Xiao H.; Ma X.; Feng W.; Fu Y.; Lu Z.; Xu M.; Shen Q.; Zhu Y.; Zhang Y.; Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway. Cardiovasc Res 2010,87(3),504-513","journal-title":"Cardiovasc Res"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.7150\/ijbs.29680","volume":"15","author":"Yang F.","year":"2019","unstructured":"Yang F.; Qin Y.; Wang Y.; Meng S.; Xian H.; Che H.; Lv J.; Li Y.; Yu Y.; Bai Y.; Wang L.; Metformin Inhibits the NLRP3 Inflammasome via AMPK\/mTOR-dependent Effects in Diabetic Cardiomyopathy. Int J Biol Sci 2019,15(5),1010-1019","journal-title":"Int J Biol Sci"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2337\/diacare.22.6.925","volume":"22","author":"Stang M.","year":"1999","unstructured":"Stang M.; Wysowski D.K.; Butler-Jones D.; Incidence of lactic acidosis in metformin users. Diabetes Care 1999,22(6),925-927","journal-title":"Diabetes Care"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2337\/diaspect.22.1.18","volume":"22","author":"Swift Maddalone T.M.","year":"2009","unstructured":"Swift Maddalone T.M.; Metformin use in patients with diabetes and heart failure: Cause for concern? Diabetes Spectr 2009,22,18-20","journal-title":"Diabetes Spectr"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1161\/CIRCHEARTFAILURE.112.000162","volume":"6","author":"Eurich D.T.","year":"2013","unstructured":"Eurich D.T.; Weir D.L.; Majumdar S.R.; Tsuyuki R.T.; Johnson J.A.; Tjosvold L.; Vanderloo S.E.; McAlister F.A.; Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 2013,6(3),395-402","journal-title":"Circ Heart Fail"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.2337\/diabetes.53.suppl_3.S48","volume":"53","author":"Henquin J-C.","year":"2004","unstructured":"Henquin J-C.; Pathways in beta-cell stimulus-secretion coupling as targets for therapeutic insulin secretagogues. Diabetes 2004,53(Suppl. 3),S48-S58","journal-title":"Diabetes"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.2337\/dc14-1306","volume":"37","author":"Li Y.","year":"2014","unstructured":"Li Y.; Hu Y.; Ley S.H.; Rajpathak S.; Hu F.B.; Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women. Diabetes Care 2014,37(11),3106-3113","journal-title":"Diabetes Care"},{"key":"ref=76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002091","volume":"13","author":"Rados D.V.","year":"2016","unstructured":"Rados D.V.; Pinto L.C.; Remonti L.R.; Leit\u00e3o C.B.; Gross J.L.; Correction: the association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med 2016,13(6)","journal-title":"PLoS Med"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"601","DOI":"10.7326\/0003-4819-157-9-201211060-00003","volume":"157","author":"Roumie C.L.","year":"2012","unstructured":"Roumie C.L.; Hung A.M.; Greevy R.A.; Grijalva C.G.; Liu X.; Murff H.J.; Elasy T.A.; Griffin M.R.; Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 2012,157(9),601-610","journal-title":"Ann Intern Med"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12933-016-0356-y","volume":"15","author":"Sonesson C.","year":"2016","unstructured":"Sonesson C.; Johansson P.A.; Johnsson E.; Gause-Nilsson I.; Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol 2016,15,37","journal-title":"Cardiovasc Diabetol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1161\/CIRCRESAHA.117.311588","volume":"122","author":"Scheen A.J.","year":"2018","unstructured":"Scheen A.J.; Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res 2018,122(10),1439-1459","journal-title":"Circ Res"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"Scirica B.M.","year":"2013","unstructured":"Scirica B.M.; Bhatt D.L.; Braunwald E.; Steg P.G.; Davidson J.; Hirshberg B.; Ohman P.; Frederich R.; Wiviott S.D.; Hoffman E.B.; Cavender M.A.; Udell J.A.; Desai N.R.; Mosenzon O.; McGuire D.K.; Ray K.K.; Leiter L.A.; Raz I.; Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med SAVOR-TIMI 53 Steering Committee and Investigators2013,369(14),1317-1326","journal-title":"N Engl J Med"},{"key":"ref=81","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109224","volume":"118","author":"Zhao T.","year":"2019","unstructured":"Zhao T.; Chen H.; Cheng C.; Zhang J.; Yan Z.; Kuang J.; Kong F.; Li C.; Lu Q.; Liraglutide protects high-glucose-stimulated fibroblasts by activating the CD36-JNK-AP1 pathway to downregulate P4HA1. Biomed Pharmacother 2019,118","journal-title":"Biomed Pharmacother"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12933-019-0857-6","volume":"18","author":"Bizino M.B.","year":"2019","unstructured":"Bizino M.B.; Jazet I.M.; Westenberg J.J.M.; van Eyk H.J.; Paiman E.H.M.; Smit J.W.A.; Lamb H.J.; Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial. Cardiovasc Diabetol 2019,18(1),55","journal-title":"Cardiovasc Diabetol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12872-016-0260-0","volume":"16","author":"Li L.","year":"2016","unstructured":"Li L.; Li S.; Liu J.; Deng K.; Busse J.W.; Vandvik P.O.; Wong E.; Sohani Z.N.; Bala M.M.; Rios L.P.; Malaga G.; Ebrahim S.; Shen J.; Zhang L.; Zhao P.; Chen Q.; Wang Y.; Guyatt G.H.; Sun X.; Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMC Cardiovasc Disord 2016,16,91","journal-title":"BMC Cardiovasc Disord"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","volume":"316","author":"Margulies K.B.","year":"2016","unstructured":"Margulies K.B.; Hernandez A.F.; Redfield M.M.; Givertz M.M.; Oliveira G.H.; Cole R.; Mann D.L.; Whellan D.J.; Kiernan M.S.; Felker G.M.; McNulty S.E.; Anstrom K.J.; Shah M.R.; Braunwald E.; Cappola T.P.; Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA NHLBI Heart Failure Clinical Research Network2016,316(5),500-508","journal-title":"JAMA"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"114","DOI":"10.2174\/1871529X18666180227102137","volume":"18","author":"Lovic D.","year":"2018","unstructured":"Lovic D.; Pittaras A.; Kallistratos M.; Tsioufis C.; Grassos C.; Djordjevic D.; Tasic I.; Manolis A.; Sodium-glucose cotransporter 2 inhibitors: Potential cardiovascular and mortality benefits. Cardiovasc Hematol Disord Drug Targets 2018,18(2),114-119","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"Zinman B.","year":"2015","unstructured":"Zinman B.; Wanner C.; Lachin J.M.; Fitchett D.; Bluhmki E.; Hantel S.; Mattheus M.; Devins T.; Johansen O.E.; Woerle H.J.; Broedl U.C.; Inzucchi S.E.; Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med EMPA-REG OUTCOME Investigators2015,373(22),2117-2128","journal-title":"N Engl J Med"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"Packer M.","year":"2020","unstructured":"Packer M.; Anker S.D.; Butler J.; Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020,383,1413-24 https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"McMurray J.J.V.","year":"2019","unstructured":"McMurray J.J.V.; Solomon S.D.; Inzucchi S.E.; K\u00f8ber L.; Kosiborod M.N.; Martinez F.A.; Ponikowski P.; Sabatine M.S.; Anand I.S.; B\u011blohl\u00e1vek J.; B\u00f6hm M.; Chiang C.E.; Chopra V.K.; de Boer R.A.; Desai A.S.; Diez M.; Drozdz J.; Duk\u00e1t A.; Ge J.; Howlett J.G.; Katova T.; Kitakaze M.; Ljungman C.E.A.; Merkely B.; Nicolau J.C.; O\u2019Meara E.; Petrie M.C.; Vinh P.N.; Schou M.; Tereshchenko S.; Verma S.; Held C.; DeMets D.L.; Docherty K.F.; Jhund P.S.; Bengtsson O.; Sj\u00f6strand M.; Langkilde A.M.; Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med DAPA-HF Trial Committees and Investigators2019,381(21),1995-2008","journal-title":"N Engl J Med"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.amjcard.2017.05.013","volume":"120","author":"Staels B.","year":"2017","unstructured":"Staels B.; Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: potential mechanisms. Am J Cardiol 2017,120(1S),S28-36","journal-title":"Am J Cardiol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1159\/000475942","volume":"41","author":"Zhou Y.","year":"2017","unstructured":"Zhou Y.; Wu W.; The sodium-glucose co-transport 2 inhibitor, empaglifozin, protects against diabetic cardiomyopathy by inhibition of the endoplasmic reticulum stress pathway. Cell Physiol Biochem 2017,41(6),2503-2512","journal-title":"Cell Physiol Biochem"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12933-019-0820-6","volume":"18","author":"Adingupu D.D.","year":"2019","unstructured":"Adingupu D.D.; G\u00f6pel S.O.; Gr\u00f6nros J.; Behrendt M.; Sotak M.; Miliotis T.; Dahlqvist U.; Gan L.M.; J\u00f6nsson-Rylander A.C.; SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob\/ob mice. Cardiovasc Diabetol 2019,18(1),16","journal-title":"Cardiovasc Diabetol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"Neal B.","year":"2017","unstructured":"Neal B.; Perkovic V.; Mahaffey K.W.; de Zeeuw D.; Fulcher G.; Erondu N.; Shaw W.; Law G.; Desai M.; Matthews D.R.; Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med CANVAS Program Collaborative Group2017,377(7),644-657","journal-title":"N Engl J Med"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/00325481.2019.1601404","volume":"131","author":"Davidson J.A.","year":"2019","unstructured":"Davidson J.A.; SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence. Postgrad Med 2019,131(4),251-260","journal-title":"Postgrad Med"},{"journal-title":"Clinical Trials gov record","year":"2018","key":"ref=94","unstructured":"A study to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease (Dapa-CKD). Clinical Trials gov record AstraZenecaAvailable at: \n2018"},{"journal-title":"Clinical Trials gov record","year":"2018","key":"ref=95","unstructured":"EMPA-KIDNEY (the study of heart and kidney protection with empagliflozin). Clinical Trials gov record Boehringer IngelheimAvailable at: \n2018"},{"key":"ref=96","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014908","volume":"9","author":"Arnott C.","year":"2020","unstructured":"Arnott C.; Li Q.; Kang A.; Neuen B.L.; Bompoint S.; Lam C.S.P.; Rodgers A.; Mahaffey K.W.; Cannon C.P.; Perkovic V.; Jardine M.J.; Neal B.; Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. J Am Heart Assoc 2020,9(3)","journal-title":"J Am Heart Assoc"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1161\/01.RES.86.5.580","volume":"86","author":"Kantor P.F.","year":"2000","unstructured":"Kantor P.F.; Lucien A.; Kozak R.; Lopaschuk G.D.; The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000,86(5),580-588","journal-title":"Circ Res"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12967-016-0849-1","volume":"14","author":"Zhang L.","year":"2016","unstructured":"Zhang L.; Ding W.Y.; Wang Z-H.; Tang M.X.; Wang F.; Li Y.; Zhong M.; Zhang Y.; Zhang W.; Early administration of trimetazidine attenuates diabetic cardiomyopathy in rats by alleviating fibrosis, reducing apoptosis and enhancing autophagy. J Transl Med 2016,14(1),109","journal-title":"J Transl Med"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.bbadis.2014.06.030","volume":"1852","author":"Varga Z.V.","year":"2015","unstructured":"Varga Z.V.; Giricz Z.; Liaudet L.; Hask\u00f3 G.; Ferdinandy P.; Pacher P.; Interplay of oxidative, nitrosative\/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy. Biochim Biophys Acta 2015,1852(2),232-242","journal-title":"Biochim Biophys Acta"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.biopha.2018.10.130","volume":"109","author":"Shi G-J.","year":"2019","unstructured":"Shi G-J.; Li Y.; Cao Q-H.; Wu H.X.; Tang X.Y.; Gao X.H.; Yu J.Q.; Chen Z.; Yang Y.; In vitro and in vivo evidence that quercetin protects against diabetes and its complications: A systematic review of the literature. Biomed Pharmacother 2019,109,1085-1099","journal-title":"Biomed Pharmacother"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.biochi.2016.03.008","volume":"125","author":"Kunasegaran T.","year":"2016","unstructured":"Kunasegaran T.; Mustafa M.R.; Murugan D.D.; Achike F.I.; The bioflavonoid quercetin synergises with PPAR-\u03b3 agonist pioglitazone in reducing angiotensin-II contractile effect in fructose-streptozotocin induced diabetic rats. Biochimie 2016,125,131-139","journal-title":"Biochimie"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4162\/nrp.2011.5.2.107","volume":"5","author":"Kim J.H.","year":"2011","unstructured":"Kim J.H.; Kang M.J.; Choi H.N.; Jeong S.M.; Lee Y.M.; Kim J.I.; Quercetin attenuates fasting and postprandial hyperglycemia in animal models of diabetes mellitus. Nutr Res Pract 2011,5(2),107-111","journal-title":"Nutr Res Pract"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.yexcr.2013.05.001","volume":"319","author":"Moreira L.","year":"2013","unstructured":"Moreira L.; Ara\u00fajo I.; Costa T.; Correia-Branco A.; Faria A.; Martel F.; Keating E.; Quercetin and epigallocatechin gallate inhibit glucose uptake and metabolism by breast cancer cells by an estrogen receptor-independent mechanism. Exp Cell Res 2013,319(12),1784-1795","journal-title":"Exp Cell Res"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1016\/j.biopha.2018.11.086","volume":"109","author":"Al Hroob A.M.","year":"2019","unstructured":"Al Hroob A.M.; Abukhalil M.H.; Hussein O.E.; Mahmoud A.M.; Pathophysiological mechanisms of diabetic cardiomyopathy and the therapeutic potential of epigallocatechin-3-gallate. Biomed Pharmacother 2019,109,2155-2172","journal-title":"Biomed Pharmacother"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1536\/ihj.18-476","volume":"60","author":"Ge Z-D.","year":"2019","unstructured":"Ge Z-D.; Lian Q.; Mao X.; Xia Z.; Current status and challenges of NRF2 as a potential therapeutic target for diabetic cardiomyopathy. Int Heart J 2019,60(3),512-520","journal-title":"Int Heart J"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","volume":"107","author":"Giacco F.","year":"2010","unstructured":"Giacco F.; Brownlee M.; Oxidative stress and diabetic complications. Circ Res 2010,107(9),1058-1070","journal-title":"Circ Res"},{"key":"ref=107","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4826724","volume":"2017","author":"David J.A.","year":"2017","unstructured":"David J.A.; Rifkin W.J.; Rabbani P.S.; Ceradini D.J.; The Nrf2\/Keap1\/are pathway and oxidative stress as a therapeutic target in type II diabetes mellitus. J Diabetes Res 2017,2017","journal-title":"J Diabetes Res"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1006\/bbrc.1997.6943","volume":"236","author":"Itoh K.","year":"1997","unstructured":"Itoh K.; Chiba T.; Takahashi S.; Ishii T.; Igarashi K.; Katoh Y.; Oyake T.; Hayashi N.; Satoh K.; Hatayama I.; Yamamoto M.; Nabeshima Y.; An Nrf2\/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997,236(2),313-322","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"637","DOI":"10.14336\/AD.2018.0513","volume":"10","author":"Tu W.","year":"2019","unstructured":"Tu W.; Wang H.; Li S.; Liu Q.; Sha H.; The Anti-inflammatory and anti-oxidant mechanisms of the Keap1\/Nrf2\/ARE signaling pathway in chronic diseases. Aging Dis 2019,10(3),637-651","journal-title":"Aging Dis"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.3390\/ijms20061492","volume":"20","author":"Cipolletta E.","year":"2019","unstructured":"Cipolletta E.; Gambardella J.; Fiordelisi A.; Del Giudice C.; Di Vaia E.; Ciccarelli M.; Sala M.; Campiglia P.; Coscioni E.; Trimarco B.; Sorriento D.; Iaccarino G.; Antidiabetic and cardioprotective effects of pharmacological inhibition of GRK2 in db\/db mice. Int J Mol Sci 2019,20(6),1492","journal-title":"Int J Mol Sci"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.1111\/jcmm.14413","volume":"23","author":"Wang X.","year":"2019","unstructured":"Wang X.; Pan J.; Liu D.; Zhang M.; Li X.; Tian J.; Liu M.; Jin T.; An F.; Nicorandil alleviates apoptosis in diabetic cardiomyopathy through PI3K\/Akt pathway. J Cell Mol Med 2019,23(8),5349-5359","journal-title":"J Cell Mol Med"},{"key":"ref=112","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012273","volume":"8","author":"West T.M.","year":"2019","unstructured":"West T.M.; Wang Q.; Deng B.; Zhang Y.; Barbagallo F.; Reddy G.R.; Chen D.; Phan K.S.; Xu B.; Isidori A.; Xiang Y.K.; Phosphodiesterase 5 associates with b2 adrenergic receptor to modulate cardiac function in type 2 diabetic hearts. J Am Heart Assoc 2019,8(15)","journal-title":"J Am Heart Assoc"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1111\/jcmm.14146","volume":"23","author":"Yin L.","year":"2019","unstructured":"Yin L.; Fang Y.; Song T.; Lv D.; Wang Z.; Zhu L.; Zhao Z.; Yin X.; FBXL10 regulates cardiac dysfunction in diabetic cardiomyopathy via the PKC \u03b22 pathway. J Cell Mol Med 2019,23(4),2558-2567","journal-title":"J Cell Mol Med"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/dmrr.1054","volume":"26","author":"Feng B.","year":"2010","unstructured":"Feng B.; Chen S.; George B.; Feng Q.; Chakrabarti S.; miR133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes Metab Res Rev 2010,26(1),40-49","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"18255","DOI":"10.1073\/pnas.0608791103","volume":"103","author":"van Rooij E.","year":"2006","unstructured":"van Rooij E.; Sutherland L.B.; Liu N.; Williams A.H.; McAnally J.; Gerard R.D.; Richardson J.A.; Olson E.N.; A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 2006,103(48),18255-18260","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12933-019-0814-4","volume":"18","author":"Rawal S.","year":"2019","unstructured":"Rawal S.; Nagesh P.T.; Coffey S.; Van Hout I.; Galvin I.F.; Bunton R.W.; Davis P.; Williams M.J.A.; Katare R.; Early dysregulation of cardiac-specific microRNA-208a is linked to maladaptive cardiac remodelling in diabetic myocardium. Cardiovasc Diabetol 2019,18(1),13","journal-title":"Cardiovasc Diabetol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12933-019-0811-7","volume":"18","author":"Yin Z.","year":"2019","unstructured":"Yin Z.; Zhao Y.; He M.; Li H.; Fan J.; Nie X.; Yan M.; Chen C.; Wang D.W.; MiR-30c\/PGC-1\u03b2 protects against diabetic cardiomyopathy via PPAR\u03b1. Cardiovasc Diabetol 2019,18(1),7","journal-title":"Cardiovasc Diabetol"}],"container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/187501","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/187501\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/187501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T05:27:35Z","timestamp":1643779655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/187501\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":117,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570161119999201102213214","relation":{},"ISSN":["1570-1611"],"issn-type":[{"type":"print","value":"1570-1611"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-05-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}